1616709-24-0

Basic information

• Product Name: 2-((5H-pyrrolo[3,4-b]pyridine-6(7H)-yl)methyl)-N-(2,4-dimethoxybenzyl)-7-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-amine
• Synonyms: 2-((5H-pyrrolo[3,4-b]pyridine-6(7H)-yl)methyl)-N-(2,4-dimethoxybenzyl)-7-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-amine
• CAS NO: 1616709-24-0
• Molecular Weight: 481.557
• Mol File: 1616709-24-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-((5H-pyrrolo[3,4-b]pyridine-6(7H)-yl)methyl)-N-(2,4-dimethoxybenzyl)-7-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-((5H-pyrrolo[3,4-b]pyridine-6(7H)-yl)methyl)-N-(2,4-dimethoxybenzyl)-7-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-amine(1616709-24-0)
• EPA Substance Registry System: 2-((5H-pyrrolo[3,4-b]pyridine-6(7H)-yl)methyl)-N-(2,4-dimethoxybenzyl)-7-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-amine(1616709-24-0)

Safety Data

• Hazardous Substances Data: 1616709-24-0(Hazardous Substances Data)

Upstream product

• 1616709-23-9 2-(chloromethyl)-N-(2,4-dimethoxybenzyl)-7-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-amine 
• 147739-88-6 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine 
• 1616709-20-6 N’-(2-chloro-8-methylquinazolin-4-yl)-2-hydroxyacetohydrazide 
• 39576-83-5 2,4,-dichloro-8-methylquinazoline 
• 1616709-21-7 N’-(2-((2,4-dimethoxybenzyl)amino)-8-methylquinazolin-4-yl)-2-hydroxyacetohydrazide 

Relevant articles and documents

HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES

Disclosed are compounds of Formula Gl (structurally represented): where "RG3" "Rd1" to "Rd4", "n", "m", "p", "W", "X", "Y", and "Z" are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDER

Disclosed are compounds of heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine herein, which have specific binding on an A2A-receptor and are useful for quantifying in vivo receptor-site occupancy of various compounds which have an affinity for binding to an A2A-receptor.